



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Leptospirosis

WIRONGRONG CHERAKUL

KEY POINTS

- Leptospirosis is caused by eight pathogenic *Leptospira* species, which have many mammalian animals as reservoirs. Humans are accidental and dead-end hosts, who contact directly or indirectly with *Leptospira*-contaminated water or animal products.
- Many infections in endemic areas are asymptomatic or oligosymptomatic.
- Clinical manifestations are those of a nonspecific acute febrile illness. Complications such as cholestatic jaundice, aseptic meningitis, acute renal injury, haemorrhage especially in the lung and myocarditis can occur and lead to a fatal outcome. Overall mortality is less than 10%.
- Clinical diagnosis is important but nonspecific. Laboratory diagnosis is not practical for patient care, but very important for epidemiology, since both culture and serology take a relatively long time.
- Differential diagnoses are dengue and other haemorrhagic fevers, malaria, scrub typhus, hepatitis, yellow fever, Hantavirus (both HPS and HFRS), enteric fever and other bacterial sepsis, especially in patients with severe complications.
- Antibiotic treatment should be given as early as possible. Doxycycline is the drug of choice in uncomplicated cases; penicillin, doxycycline, ceftriaxone and cefotaxime are efficacious alternatives in severe cases.
- No effective human vaccine available, protection from contact is crucial. Weekly doxycycline chemoprophylaxis in very high-risk groups is also effective.

Introduction

Leptospirosis is a worldwide zoonotic disease caused by pathogenic *Leptospira* species. The disease presents in both tropical and temperate zones. The major reservoirs of the organisms are cattle, horses, canines and rodents. Humans are accidentally infected through contact with contaminated water. The symptoms range from mild or asymptomatic to severe fatal illness. The severe illness, characterized by febrile illness with jaundice, acute renal injury and bleeding, is recognized as Weil's disease, though many different local names have been used such as Fort Bragg, mud, swamp and sugar cane fevers. Specific treatment with antibiotics is valuable at all stages of the illness and prevents development of severe disease. In severely ill patients, intensive care supportive treatment is crucial.

Causative Agents

Molecular biology studies have led to major advances in our understanding of *Leptospira* spp. during the past decade. *Leptospira* are spiral bacteria (spirochaete) in the family of Leptospiraceae. There are eight pathogenic, seven non-pathogenic *Leptospira* species, and five intermediate species with unknown ability for causing disease. *Leptospira interrogans* and *L. borgpetersenii* are the two most common species causing diseases in human and animals. The schematic classification of the organisms is shown in Figure 37.1.

The old phenotypic classification of *Leptospira*, based on serology using the cross-agglutination absorption test (CAAT) is still in use. Approximately 250 pathogenic serovars, grouped by related antigenicity into 24 serogroups, have been identified to date. The concept of a serovar is complicated and may fail to define epidemiologically important strains. Serovars of the same serogroup may distribute between different species identified by DNA-DNA hybridization (Table 37.1).^{1,2} The current recommendation for *Leptospira* nomenclature is using species name followed by the term 'serovar' and serovar name with initial capital letter and non-italic, e.g. *Leptospira interrogans* serovar Autumnalis.

The whole genomes of two pathogenic (*L. interrogans* and *L. borgpetersenii*) and a non-pathogenic species (*L. biflexa*) have been sequenced. *L. interrogans* has 35–41% GC content in two circular chromosomes of approximately 4 Mb and 300 Kb in size. *L. borgpetersenii* has a smaller genome (3.9 Mb) and a larger proportion of pseudogenes (20%), compared with *L. interrogans*. This may impair the ability of *L. borgpetersenii* to survive in the external environment, and so require direct contact between hosts to maintain the transmission cycle.^{3,4}

Recent developments in molecular typing have characterized relationships between pathogenic strains and assisted outbreak investigation and epidemiology. Several typing techniques have been developed. One is the sequence-based approach, multilocus sequence typing (MLST). Using MLST the major outbreak of leptospirosis in Thailand during 1996–2000 was shown to have been caused by one successive clone, strain type (ST) 34 of *L. interrogans* serovar Autumnalis. (MLST has been used to create a standard global database for typing and mapping strains of *Leptospira*, see: <http://leptospira.mlst.net>).⁵

Life Cycle and Transmission

A wide range of mammalian species, including rodents, cattle, pigs, domestic and wild animals, are the major reservoirs and carriers, whereas humans are mostly accidental and dead end hosts. The infecting organism is sustained naturally by chronic infection of the renal tubules of maintenance hosts after primary




Figure 37.1 Classification of *Leptospira*.

infection. The organisms are usually transferred from animal to animal by direct contact. The maintenance hosts or carriers can excrete *Leptospira* in their urine for long periods of time or for their entire lives. Leptospire survive weeks or months in moist and warm soil, stagnant water at neutral or slightly alkaline pH. Humans are infected via direct contact with infected animal urine, animal abortion products or most commonly through indirect contact with infected urine-contaminated water. The oral route of transmission had been reported in water-borne fatal outbreaks in Portugal, Greece, Russia, Italy and India.^{2,6,7} Breast milk transmission may occur.⁸ Sexual and vertical transmission in humans occurs rarely.

Humans at risk for leptospirosis are those with occupational exposure. These include farmers, fishermen, miners, animal slaughterers, veterinarians, sewage and canal workers, sugar cane workers, soldiers, etc. Special events and activities clearly related to the diseases are recreational water sports, including triathlon, canoeing and white-water rafting, and natural disasters, such as hurricanes, floods, etc. Laboratory-acquired infection may occur when dealing with high concentrations of organisms in culture.

Epidemiology

The true global burden is largely unknown both in human and animals. Leptospirosis occurs in tropical, subtropical and temperate regions. The disease is often under-recognized and neglected because of the difficulties confirming the diagnosis. Furthermore many infections in endemic areas are asymptomatic or oligosymptomatic. The six highest incidences reported are from the Indian Ocean and Caribbean Sea islands (Seychelles, Trinidad and Tobago, Barbados, Jamaica, Costa Rica and Sri Lanka). Countries in South-east Asia, except Thailand and Singapore, have no official incidence data, so the true incidence is unknown.⁹

The Leptospirosis Burden Epidemiology Reference Group (LERG) set up by World Health Organization (WHO) is trying

to assess the global burden of human leptospirosis, and thereby hopefully, will inform rational deployment of effective control and preventive measures.¹⁰ According to the second report of LERG in 2010, the median global incidence of human leptospirosis, excluding outbreak cases, was five cases per 100 000 population. The incidence by WHO regions from highest to lowest were Africa, Western Pacific, America, South-east Asia, and Europe, with the median (range) of 95.5 (62.8–160.2), 66.4 (1.1–975.0), 12.5 (0.1–306.2), 4.8 (0.3–7.3) and 0.5 (0.1–15.8) cases/100 000 population, respectively. There were no data available from the Eastern Mediterranean in this report.¹¹

Leptospira serovars show specific, but not exclusive, host preferences. For example, *L. borgpetersenii* serovar Hardjo predominates in farm animals especially cattle, *L. interrogans* serovar Canicola circulates mainly in dogs. The incidence of leptospirosis is seasonal in several countries, mostly related to rainfall.

Pathogenesis, Pathology and Immunology

After skin or mucosal penetration, the organisms cross the tissue barriers through intercellular junctions. Leptospire can be detected in the bloodstream shortly after penetration into the body, and from some organs within three days after infection. Leptospire are rarely observed within host cells. However, they can reside transiently within cells while crossing cell barriers. The organisms can evade host immune response during the initial phase of infection through unclear mechanisms. They are resistant to the alternative pathway of complement activation and acquire complement factor H and related fluid-phase regulators through ligands such as leptospiral endostatin-like A (LenA) proteins.¹² Recent data show that pathogenic leptospire can bind human plasminogen (PLG), and plasmin activity on the bacterial surface interferes with complement C3b and IgG deposition, therefore decreasing opsonization of the organisms.¹³ Lipopolysaccharide (LPS) of pathogenic leptospire can activate Toll-like receptor 2 (TLR2) but not TLR4 pathway, and activate the production of pro-inflammatory cytokines mediating inflammation and damaging end-organ tissues.¹⁴

Comparison of putative pathogenicity factors with the saprophyte, *L. biflexa* has identified several pathogenic processes. These can be divided into three components; *adhesins* (proteoglycans, LenA, 36 kDa outer surface membrane protein, 24 and 21 kDa laminin binding protein (Lsa24, Lsa21), Leptospiral immunoglobulin-like proteins (Lig A, Lig B and Lig C proteins); *evasion of natural defences or phagocytosis*; and *resistance to complement* as described above. Unlike other Gram-negative bacteria, the lipopolysaccharides (LPS) of leptospire cause minor endotoxicity, while leptospiral outer membrane lipoproteins (OMPs), such as Lip32, Loa22 play a major role as virulence factors.¹⁵

Although the early phase of the disease does not cause much inflammation, hepatocellular and tubular damage can occur. Liver pathology ranges from no appreciable changes, unicellular damage with oedema, to spotty necrosis surrounded by mononuclear cells without hepatocyte ballooning or swelling. Complete liver cell necrosis is not unusual. Kupffer cells and sinusoidal lining cells may show swollen cytoplasm. Biliary stasis with bile droplets in hepatocytes and bile thrombi in the canaliculi is prominent in the centrilobular areas, with

biliary capillary microvilli disappearance and distortion, indicating cholestasis.¹⁶ Renal pathology is mainly tubulointerstitial nephritis. In severe cases, tubular necrosis and medullary tubular cell desquamation can occur. Glomeruli contain exudates and inflammatory cell infiltration, but are usually spared.¹⁷ Primary injury of the proximal convoluted tubules is regarded as the hallmark of renal pathology, especially affecting sodium and water transportation.¹⁸ Recently developed *in situ* hybridization assays and immunohistochemistry suggest that cell membrane damage in both the liver and kidney may be important in pathogenesis.¹⁹

Vasculitis is a prominent feature of leptospirosis. Endothelial damage and increased capillary fragility lead to internal organ haemorrhage. Disseminated intravascular coagulation (DIC) is not obvious in the pathology in fatal cases. However, with new definitions and sensitive markers for detection of DIC, patients with leptospirosis do have significantly elevated fibrinogen, D-dimer, thrombin-antithrombin III complexes, and prothrombin fragment 1,2. Using DIC scores, defined by the DIC scientific subcommittee of the International Society of Thrombosis and Haemostasis, overt DIC was evident in nearly half of patients.²⁰ Fatal bleeding usually occurs in the lung, with fibrin aggregation suggestive of adult respiratory distress syndromes (ARDS) in nearly 60% of fatal cases. Capillary lesions characterized by swollen endothelial cells with an increase in pinocytotic vesicles and haemorrhagic pneumopathy with septal capillary lesions were present.²¹

Clinical Features

The average incubation period is 5–14 days, with a range of 2–30 days.²² The clinical spectrum is extremely broad; ranging from subclinical or asymptomatic, mild insignificant, self-limited symptoms, to severe fatal manifestations. A substantial proportion of people in endemic areas infected with leptospirosis may have subclinical disease evidenced only by serology. Leptospirosis is an important cause of acute undifferentiated fever. In the Seychelles, 37% and 9% of screened people had past and recent infections respectively, though none of them reported any recognizable symptoms of leptospirosis.²³ The reasons for protean manifestations are unclear. There were some reports of serovar-specific presentations and serovar-related severity, such as serovar Icterohaemorrhagiae and hepatorenal syndrome (pulmonary haemorrhage and renal failure), serovar Copenhageni and uveitis, serovar Bataviae with neurological preference.

The classical manifestation of leptospirosis has been described as ‘biphasic’ pattern, an early nonspecific leptospiraemic phase lasts for a week followed by an immune phase with complications during the second week of illness. This biphasic course of leptospirosis dictates the selection of specimens for laboratory diagnosis, since it describes the phase of leptospires and the immunologic response in human hosts. The fever too may be biphasic.²⁴ Complications such as jaundice, acute renal injury, haemorrhage, especially pulmonary haemorrhage, aseptic meningitis, myocarditis, shock, occur early during the course of illness. Direct invasion of leptospires and the host-response cause organ damage although specific immune responses may not be measurable until the second week of illness. Certain distinctive complications, such as uveitis, usually occur as a late complication months later, sometimes without detectable clinical symptoms during the acute infection.

The majority of patients are mild, self-limited ‘flu-like’ symptoms and may not seek medical attention. A small proportion of patients present with sudden onset of febrile illness and non-specific symptoms, such as headache, myalgia, backache, abdominal pain, conjunctival suffusion, chills, diarrhoea, anorexia, transient rash, cough, sore throat, etc. Myalgia can be mild or severe accompanied by muscle tenderness and elevated muscle enzyme (creatinine phosphokinase; CPK) levels in serum. Hepatomegaly may develop, but splenomegaly is unusual. Severe leptospirosis is a multi-system disease. Nearly 60% of patients develop the following complications during the course of illness.

HYPOTENSION

Shock is a common presenting sign of leptospirosis, and may occur in 45% of patients. This results from several factors, including hypovolaemia from low fluid intake compounded by increased capillary permeability and vasodilatation from high fever, microvascular dysregulation, inflammatory responses to the high levels of bacteraemia, and low cardiac output from myocarditis and dysrhythmias. The majority of shocked patients will respond to fluid replacement and low-dose inotropic agents, but in severe myocarditis and patients with sepsis-like syndrome, the prognosis of profound shock is poor.

HEPATIC DYSFUNCTION

Jaundice is a notable feature of severe leptospirosis. The proportion of patients with jaundice was reported as ranging widely from less than 20% up to more than 70%. Extreme elevations of bilirubin may occur. Jaundice in leptospirosis is associated with cholestasis rather than hepatocellular damage, reflected by a characteristic dissociation between the slight elevations in transaminase and alkaline phosphatase concentrations despite the exceedingly high bilirubin levels. The prothrombin time may be slightly prolonged. Severe hepatic necrosis and fatal liver failure does occur rarely. Jaundice usually appears on days 3–6 (up to 9 days) after the onset of illness, and is not associated with pruritus. Haemolysis may also contribute to the degree of jaundice. Liver enlargement can be prominent in severe cases.

RENAL COMPLICATIONS

Renal involvement is an important manifestation of severe leptospirosis. In mild cases, the only abnormal findings are in the urinary sediment. These include albuminuria, microscopic haematuria, pyuria and the presence of granular casts in freshly examined urine. Renal impairment may be attenuated by dehydration from low fluid intake and high fever. Therefore, careful supportive treatment is very important. Presenting symptoms can be non-oliguric, oliguric or anuric in severe cases. Renal insufficiency commonly occurs together with jaundice, and is usually evident within the first 3–4 days of illness, followed by a rapid rise of plasma urea and creatinine often requiring renal replacement therapy. Hyperkalaemia from acute renal injury can occur, but hypokalaemia due to impairment of sodium transporters in the proximal tubules and spared function of the distal tubules is more common. The polyuric phase may develop after 10–18 days, and the serum creatinine begins to fall at the end of the second week and normalizes within 3–5 weeks after

the onset of illness as in other causes of acute tubulointerstitial nephritis. Renal injury from leptospirosis is never permanent.

PULMONARY COMPLICATIONS

Pulmonary involvement occurs in 20–70% of cases. This is mostly mild and often overlooked, but can be serious, leading to death. The severity of the pulmonary involvement is unrelated to liver dysfunction. The most common symptom is cough, with or without secretions. Blood-tinged sputum or obvious haemoptysis may occur. Abnormal radiological findings are found in more than half of patients despite the absence of respiratory symptoms. Many different abnormalities can be found, including localized lesions such as lobar, confluent, or patchy infiltrations, or diffuse reticulonodular or interstitial infiltration. Pulmonary haemorrhage usually presents with nodular or patchy infiltration, and sometimes with localized confluent consolidation, isolated interstitial infiltration is uncommon. Pulmonary oedema with cardiomegaly due to volume overload or congestive heart failure from myocarditis and diffuse ground glass appearance without cardiomegaly reflecting ARDS are both observed and sometimes are difficult to distinguish. This fatal complication can occur as early as 2–3 days after onset of fever. Pulmonary haemorrhage can be minimal or severe diffused leading to respiratory failure and is the leading cause of fatal outcome.

CARDIAC AND VASCULAR COMPLICATIONS

Cardiac involvement in leptospirosis is relatively common but often goes unnoticed. The most common finding is slight PR interval prolongation on the electrocardiogram (ECG), although other more severe conduction abnormalities may occur. Atrial fibrillation is the most common dysrhythmia. Fatal arrhythmias such as ventricular tachycardia seldom occur. These ECG changes and arrhythmias usually resolve after treatment. Myocarditis, pericarditis, aortitis, arteritis of coronary and cerebral arteries and vasculitis have been reported, and may contribute to an unfavourable outcome.

OCULAR COMPLICATIONS

Conjunctival suffusion is prominent in patients with leptospirosis, and subconjunctival haemorrhage is a common sign. Subconjunctival haemorrhage is found more frequently compared with patients with scrub typhus (which commonly coexists in endemic areas of East Asia), whereas red eyes happen equally in both diseases. More serious complications to the eyes are vitreous oedema or haemorrhages, and retinal haemorrhages which occur as early complications, or uveitis and anterior iridocyclitis as late complications, which may lead to permanent disturbance of vision.

NEUROLOGICAL COMPLICATIONS

Several forms of central nervous system involvement have been reported. The most common neurological complication is aseptic lymphocytic meningitis which occurs in 11–25% of patients. Patients usually present with severe headache, photophobia and nuchal rigidity accompanying the onset of fever. *Leptospira* can be isolated from cerebrospinal fluid (CSF) within 5 days after onset of fever. The usual findings are a raised CSF

opening pressure, raised protein with normal CSF glucose level and lymphocytic pleocytosis. The CSF is culture negative for fungi or other aerobic bacteria. Thus the main differential diagnosis is viral meningitis. Seizure is rare and usually occurs late after the onset of other complications.

Other uncommon reported neurological manifestations include encephalomyelitis, polyneuropathies, Guillain–Barré syndrome, mononeuritis multiplex, cranial or peripheral nerve palsies. Patients may present with a psychiatric syndrome characterized by mania, or may have mood instability as a rare complication which may persist for years.

BLEEDING DIATHESSES

Besides pulmonary haemorrhage, abnormal bleeding may be observed in other areas, such as gastrointestinal bleeding, epistaxis, gum bleeding, vaginal bleeding, and skin bleeding presenting as petechiae or ecchymoses. Bleeding in vital organs with fatal sequelae have been reported in the adrenal glands and subarachnoid space. The mechanism of bleeding is unclear, but several factors contribute. These include thrombocytopenia, capillary endothelial damage, and coagulation defects resulting from hepatic dysfunction, consumptive coagulopathy and DIC.

OTHER COMPLICATIONS

Patients with serositis may occasionally present with severe abdominal pain and peritonism. Sometimes the abdominal pain is severe and indistinguishable from appendicitis, acute cholecystitis or cholangitis, especially in jaundiced patients, leading to unnecessary intra-abdominal surgery. Acute pancreatitis has been reported rarely, although serum amylase may be raised in up to 60% of patients with severe disease due to renal impairment. Leptospirosis in pregnancy may result in abortion, postpartum haemorrhage and intrauterine fetal death. Congenital leptospirosis occurs rarely. Other rare complications include erythema nodosum, life-threatening rhabdomyolysis associated with renal failure, and reactive arthritis.

These complications appear in variable proportions and can overlap. Weil's disease was first described by a German doctor, Professor Adolf Weil, in 1886 in four patients with a febrile illness together with severe nervous symptoms, hepatosplenomegaly, jaundice and signs of renal disease which recovered rapidly. Nowadays, the term 'Weil's syndrome' usually refers to the extremely severe form of leptospirosis, characterized by the combination of jaundice, renal dysfunction, and haemorrhagic diathesis, especially pulmonary haemorrhage. This syndrome occurs in less than 10% of patients and carries a mortality rate of 5–40%. Overall mortality of patients hospitalized with leptospirosis varies among countries and series reports, and usually does not exceed 10%.

Laboratory Findings

Anaemia is a prominent finding especially in severe cases, partly due to blood loss and haemolysis. White blood cell count can be normal (50%) or elevated with the median WBC count around $10\text{--}11 \times 10^9/\text{L}$ and more than 80% neutrophil, with elevation of erythrocyte sedimentation rate and C-reactive protein concentrations. White blood cell counts higher than $13\,000/\text{mm}^3$ are associated with poorer outcomes. The bleeding, prothrombin and activated partial thromboplastin times can be

prolonged in 50% of patients. Thrombocytopenia, a platelet count $\leq 100 \times 10^9/L$, occurs in 40–60% of patients. Thrombocytopenia is an indicator of severe disease and risk of bleeding.

Differential Diagnosis

Acute febrile illness accompanied by jaundice and renal failure should always include leptospirosis in the differential diagnosis. A history of either indirect exposure to possible contaminated water or direct contact with animals occupationally or recreationally increases the probability of the diagnosis. Many patients from the same community presenting with similar symptoms within a short period of time alerts to the likelihood of an outbreak and intervention may be needed to minimize the number of severe and fatal cases. However, the symptoms and signs of leptospirosis are not specific and can mimic many other acute febrile illnesses in endemic areas.

In patient with marked jaundice, viral hepatitis has to be excluded. Biliary tract infection may mimic leptospirosis especially in patients with severe upper abdominal pain. Since the disease is found worldwide, the list of differential diagnoses is broad and may differ among different geographical areas. Table 37.2 shows the differential diagnosis of leptospirosis according to symptoms and regions. Of these, rickettsioses, especially scrub typhus, carries the same clinical spectrum and geographical distribution of the disease and completely overlaps with leptospirosis in Asia-Oceania. There have been several reports of co-infections from the South-east Asia regions. Sepsis is difficult to rule out in patients with severe forms, and co-infections can also occur. *Hantavirus*, which cause haemorrhagic fever with renal syndrome and is associated with rodent exposure,

has similar epidemiology and clinical manifestations as leptospirosis. In addition, dual infection of leptospirosis and *Hantavirus* has been reported.

Diagnosis

The clinical diagnosis of leptospirosis cannot be certain because of the nonspecific symptoms and signs which overlap with those of other common febrile diseases. In endemic areas, awareness should be raised during the rainy season. In some circumstances, such as natural disasters with fresh water exposure, health care workers should be alert for outbreaks. A definite diagnosis of leptospirosis is based on the isolation of *Leptospira* from clinical specimens (mainly from blood or CSF), or a positive microscopic agglutination test (MAT), both of which are laborious and not widely available.

ISOLATION OF PATHOGENIC LEPTOSPIRA

Although *Leptospira* can survive in some commercial aerobic bacteria culture bottles, the recommended media used for isolation is the semi-solid Ellinghausen, McCullough, Johnson, and Harris (EMJH) medium. Cultures are usually kept at 28–30°C without CO₂ incubation. It may take 2–3 weeks for *Leptospira* to multiply to detectable densities. Cultures should be examined weekly by dark field microscopy. This technique is not routine practice in a standard microbiological laboratory.

Recently, a new solid medium called LVW agar was developed. It can increase the growth rate of *Leptospira*. Using this

TABLE 37.2 Differential Diagnosis of Leptospirosis According to Symptoms and Regions

Clinical Symptoms	Europe	North America	South America	Africa	Asia-Oceania
Acute febrile illness	Enteric fever Chikungunya (severe joint pain) Tularemia (skin lesion) Relapsing fever (sporadic-Middle East)	Rickettsioses RMSF (rash) Epidemic typhus Ehrlichiosis Relapsing fever (sporadic)	Malaria Rickettsioses Spotted Fever Group (skin lesions) Epidemic typhus Enteric fever Bartonellosis Tularemia (skin lesion) Brucellosis Schistosomiasis Dengue fever Acute American trypanosomiasis Relapsing fever (sporadic)	Malaria Dengue fever Schistosomiasis Chikungunya (severe joint pain) Acute African trypanosomiasis Relapsing fever (sporadic) Rickettsioses Epidemic typhus Spotted Fever Group (skin lesions)	Malaria Rickettsioses Scrub typhus (eschar) Murine typhus Spotted Fever Group (skin lesions) Enteric fever Dengue fever Chikungunya (severe joint pain)
Acute febrile illness with haemorrhage	Meningococcaemia	<i>Hantavirus</i> (HFRS) DHF	Meningococcaemia Yellow fever (vaccination) <i>Hantavirus</i> (HFRS) DHF Junin virus Machupo virus Sabia virus Guanarito virus	Meningococcaemia Yellow fever (vaccination) DHF <i>Hantavirus</i> (HFRS) Lassa fever Rift Valley fever Ebola Marburg viruses	Meningococcaemia DHF
Acute febrile illness with pulmonary involvement	Influenza	Influenza <i>Hantavirus</i> (HPS) SARS	Influenza <i>Hantavirus</i> (HPS)	Influenza <i>Hantavirus</i> (HPS)	Influenza SARS Meliodiosis Rickettsioses

DHF, Dengue haemorrhagic fever; HPS, Hantavirus pulmonary syndrome; HFRS, haemorrhagic fever with renal syndrome; SARS, severe acute respiratory syndrome; RMSF, Rocky Mountain spotted fever.




Figure 37.2 E-test of *Leptospira* performed on a novel LVW solid agar. (Courtesy of Vanaporn Wuthiekanun.)

novel agar, simple antimicrobial susceptibility testing, using the E-test can provide clear cut-offs and easy-to-read minimal inhibitory concentrations (MIC) of antimicrobials currently recommended for treatment (Figure 37.2). The novel LVW agar may open a new era in the clinical practice for diagnosis and rapid antimicrobial susceptibility testing of leptospirosis.²⁵

Isolation of leptospire should be performed from blood or CSF of untreated patients who present not later than 5 days after onset of illness. Antibiotic pre-treatment substantially decreases the yield of the isolation. Isolation from urine is less useful, since leptospiuria usually occurs during the second week in which antibiotics have been given and antibodies are readily detectable. The acidity of the urine reduces the sensitivity of culture.

SEROLOGY TESTS

The gold standard serological test is MAT. The test is serovar-specific and useful for epidemiological studies. It detects mixed IgG and IgM. The MAT test is considered positive if there is either a fourfold rise of the convalescent titre compared to the acute titre, or there is a titre of more than or equal to 1:400 in single or paired sera. This may not be useful for patient care,

since the diagnosis is usually obtained late. The test can be performed to a reliable standard in only a few places. New simplified confirmatory methods are urgently needed.

Several other serological tests have been developed and used in many places, although the sensitivity, specificity and accuracy of the tests are generally unsatisfactory. All of these tests are non-serovar-specific, so they have no epidemiological usefulness, and are used for screening purposes only. Examples of these tests are the immunochromatographic test (ICT) or cassette test, microcapsule agglutination test (MCAT), and latex agglutination test (LA).

MOLECULAR METHODS

Standard PCR diagnostics are not available for leptospirosis. PCR methods using various target genes have been developed. Real time PCR may be a good candidate for future confirmatory tests.

Management and Treatment

Leptospira are broadly sensitive to many antibiotics; however the efficacy of antibiotic treatment has been confirmed in only small series. Because of the biphasic course of the disease, the usefulness of antibiotic treatment has been doubted when given in the second immune phase. There are insufficient randomized controlled trial data to provide clear evidence on the efficacy of treatment at different stages of the infection. There have been seven randomized controlled trials; four trials with 403 patients compared an antibiotic with placebo or no intervention. Penicillin shortened the fever time, times to normalization of creatinine level and hospitalization in a small randomized, placebo-controlled trial even late in the course of disease in Thailand, but showed a non-significant trend to reduction in mortality in Brazil when given after 4 days of illness. Despite these uncertainties effective treatment should be given in every patient as soon as possible at any stage of the disease. The recommended drugs and doses are shown in Table 37.3. All regimens, except 3-day azithromycin, should be given for 7 days. Penicillin, cefotaxime and ceftriaxone can be switched to oral amoxicillin if patients improve and can tolerate oral drug treatment.

Oral doxycycline remains the drug of choice in uncomplicated cases of leptospirosis. Alternative choices for patients with

TABLE 37.3 Treatment of Leptospirosis

	Drug	Dose	Route of Administration	Adverse Effect and Remarks
Uncomplicated leptospirosis	Doxycycline	100 mg (2 mg/kg) twice daily	Oral	Take with meal to prevent GI irritation Avoid strong sunlight exposure to prevent photosensitivity
	Amoxicillin	1 g (20 mg/kg) twice daily	Oral	
	Azithromycin	1 g (20 mg/kg) initially then 500 mg (10 mg/kg) once daily	Oral	
Moderate and severe complicated leptospirosis	Doxycycline	200 mg (4 mg/kg) initially then 100 mg (2 mg/kg) 12 hourly	Infused in 30 minutes	Not available in many countries
	Penicillin G Sodium	1.5 mU (30000 U/kg) 6 hourly	Intravenous	Hypersensitivity precaution
	Ceftriaxone	1 g (20 mg/kg) once daily	Intravenous	
	Cefotaxime	1 g (20 mg/kg) 6 hourly	Intravenous	

hypersensitivity and pregnant or lactating woman are oral amoxicillin or azithromycin. In severe cases, penicillin, doxycycline, ceftriaxone and cefotaxime have similar efficacy. However, in South-east Asia, the use of doxycycline or a cephalosporin in combination with doxycycline are recommended because scrub typhus co-infection is common.

Supportive care in severely ill patients is critical in leptospirosis. Careful fluid resuscitation should be given in patients with hypovolaemic shock. Inotropic drug administration should be given to patients with refractory shock despite effective fluid replacement. Haemodialysis should be started early in patients with hypercatabolic renal injury. Daily haemofiltration or dialysis may be needed in some patients, and renal replacement should be continued until clear improvement. Bleeding precautions are needed; however, routine use of proton-pump inhibitors and H2 blockers is not recommended and should be used with caution, especially in patients who are intubated, as they may increase the occurrence of ventilator-associated pneumonia. Respiratory support is mandatory in patients with respiratory failure either from ARDS or severe pulmonary haemorrhage. Ventilation should be supervised in the intensive care unit care to maintain adequate oxygenation. The use of high-dose steroids is not indicated and may be harmful predisposing to superimposed bacterial infections.²⁶

Prevention and Control

People at risk of exposure and people living in endemic areas should be informed about the disease and the risks. The education of people at risk and awareness of healthcare workers enable early detection and treatment. Reducing rodent populations in housing and working areas may reduce the risk of exposure. However, the disease circulates mainly in mammals other than rodents. Immunization of domestic farm animals and pets reduces the overall risks to humans significantly. The use of personal protective measures such as long boots, gloves and protective clothing are recommended and should be emphasized in all workers at risk.

Chemoprophylaxis is recommended in people at particularly high risk. Doxycycline is effective for prevention when given at 200 mg weekly during high-risk exposure. The main adverse effect is gastrointestinal irritation causing vomiting, so the drug should be administered with food.²⁷ Human serovar-specific, short-term protective vaccines are available in China, Cuba, France and Russia. The efficacy of the vaccines in other areas have never been evaluated. Genome sequencing of all pathogenic *Leptospira* species may provide the opportunity to identify new vaccine candidates which ultimately aim to protect against all eight pathogenic *Leptospira* species.¹⁰

REFERENCES

1. Cerqueira GM, Picardeau M. A century of *Leptospira* strain typing. *Infect Genet Evol* 2009;9(5):760–8.
10. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. *Clin Microbiol Infect* 2011;17(4):494–501.
15. Cinco M. New insights into the pathogenicity of leptospires: evasion of host defences. *New Microbiol* 2010;33(4):283–92.
25. Wuthiekanun V, Amornchai P, Paris DH, et al. Rapid isolation and susceptibility testing of *Leptospira* spp. using a new solid medium, LVW agar. *Antimicrob Agents Chemother* 2013;57(1):297–302.
27. Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis. *Cochrane Database Syst Rev* 2009;(3):CD007342.

Access the complete references online at www.expertconsult.com.

REFERENCES

1. Cerqueira GM, Picardeau M. A century of *Leptospira* strain typing. *Infect Genet Evol* 2009;9(5):760–8.
2. Levett PN. Leptospirosis. *Clin Microbiol Rev* 2001;14(2):296–326.
3. Bulach DM, Zuerner RL, Wilson P, et al. Genome reduction in *Leptospira borgpetersenii* reflects limited transmission potential. *Proc Natl Acad Sci U S A* 2006;103(39):14560–5.
4. Picardeau M, Bulach DM, Bouchier C, et al. Genome sequence of the saprophyte *Leptospira biflexa* provides insights into the evolution of *Leptospira* and the pathogenesis of leptospirosis. *PLoS One* 2008;3(2):e1607.
5. Thaipadungpanit J, Chierakul W, Wuthiekanun V, et al. Diagnostic accuracy of real-time PCR assays targeting 16S rRNA and lipL32 genes for human leptospirosis in Thailand: a case-control study. *PLoS One* 2011;6(1):e16236.
6. Cacciapuoti B, Ciceroni L, Maffei C, et al. A waterborne outbreak of leptospirosis. *Am J Epidemiol* 1987;126(3):535–45.
7. Ramakrishnan R, Patel MS, Gupte MD, et al. An institutional outbreak of leptospirosis in Chennai, South India. *J Commun Dis* 2003;35(1):1–8.
8. Bolin CA, Koellner P. Human-to-human transmission of *Leptospira interrogans* by milk. *J Infect Dis* 1988;158(1):246–7.
9. Pappas G, Papadimitriou P, Siozopoulou V, et al. The globalization of leptospirosis: worldwide incidence trends. *Int J Infect Dis* 2008;12(4):351–7.
10. Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. *Clin Microbiol Infect* 2011;17(4):494–501.
11. WHO. Report of the second meeting of the leptospirosis burden epidemiology reference group. Geneva: World Health Organization; 2011. Online. Available: <http://www.who.int/zoonoses/diseases/lerg/en/>.
12. Ko AI, Goarant C, Picardeau M. *Leptospira*: the dawn of the molecular genetics era for an emerging zoonotic pathogen. *Nat Rev Microbiol* 2009;7(10):736–47.
13. Vieira ML, de Moraes ZM, Vasconcellos SA, et al. In vitro evidence for immune evasion activity by human plasmin associated to pathogenic *Leptospira interrogans*. *Microb Pathog* 2011;51(5):360–5.
14. Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. *Nat Immunol* 2001;2(4):346–52.
15. Cinco M. New insights into the pathogenicity of leptospires: evasion of host defences. *New Microbiol* 2010;33(4):283–92.
16. De Brito T, Machado MM, Montans SD, et al. Liver biopsy in human leptospirosis: a light and electron microscopy study. *Virchows Arch Pathol Anat Physiol Klin Med* 1967;342(1):61–9.
17. De Brito T, Penna DO, Pereira VC, et al. Kidney biopsies in human leptospirosis: a biochemical and electron microscopy study. *Virchows Arch Pathol Anat Physiol Klin Med* 1967;343(2):124–35.
18. Araujo ER, Seguro AC, Spichler A, et al. Acute kidney injury in human leptospirosis: an immunohistochemical study with pathophysiological correlation. *Virchows Arch* 2010;456(4):367–75.
19. De Brito T, Menezes LF, Lima DM, et al. Immunohistochemical and in situ hybridization studies of the liver and kidney in human leptospirosis. *Virchows Arch* 2006;448(5):576–83.
20. Chierakul W, Tientadakul P, Suputtamongkol Y, et al. Activation of the coagulation cascade in patients with leptospirosis. *Clin Infect Dis* 2008;46(2):254–60.
21. Nicodemo AC, Duarte MI, Alves VA, et al. Lung lesions in human leptospirosis: microscopic, immunohistochemical, and ultrastructural features related to thrombocytopenia. *Am J Trop Med Hyg* 1997;56(2):181–7.
22. Faine S. *Leptospira and leptospirosis*. 2nd ed. Melbourne: MediSci; 1999.
23. Bovet P, Yersin C, Merien F, et al. Factors associated with clinical leptospirosis: a population-based case-control study in the Seychelles (Indian Ocean). *Int J Epidemiol* 1999;28(3):583–90.
24. Turner LH. Leptospirosis. I. *Trans R Soc Trop Med Hyg* 1967;61(6):842–55.
25. Wuthiekanun V, Amornchai P, Paris DH, et al. Rapid isolation and susceptibility testing of *Leptospira* spp. using a new solid medium, LVW agar. *Antimicrob Agents Chemother* 2013;57(1):297–302.
26. Niwattayakul K, Kaewtasi S, Chueasuwanchai S, et al. An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct therapy in patients with pulmonary involvement associated with severe leptospirosis. *Clin Microbiol Infect* 2010;16(8):1207–12.
27. Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis. *Cochrane Database Syst Rev* 2009;(3):CD007342.